The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
Open accessAbstract
The pathophysiological process of Alzheimer's disease (AD) is thought to begin many years before the diagnosis of AD dementia. This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms. The National Institute on Aging and the Alzheimer's Association convened an international workgroup to review the biomarker, epidemiological, and neuropsychological evidence, and to develop recommendations to determine the factors which best predict the risk of progression from “normal” cognition to mild cognitive impairment and AD dementia. We propose a conceptual framework and operational research criteria, based on the prevailing scientific evidence to date, to test and refine these models with longitudinal clinical research studies. These recommendations are solely intended for research purposes and do not have any clinical implications at this time. It is hoped that these recommendations will provide a common rubric to advance the study of preclinical AD, and ultimately, aid the field in moving toward earlier intervention at a stage of AD when some disease‐modifying therapies may be most efficacious.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The susceptibility of the conventional criteria for MCI to diagnostic error is likely to be amplified if used to characterize and stage preclinical AD—a pre-MCI categorization based on subtle cognitive decline [8].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [8]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In PET imaging, PIB and Florbetapir (AV45) amyloid tracers have shown greater cortical uptake in patients diagnosed with AD compared with control participants 11,57 .”
From OASIS-3: Longitudinal Neuroimaging, Clinical, and Cognitive Dataset for Normal Aging and Alzheimer Disease (2019) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several anti-Aβ therapeutic strategies are being pursued to treat AD; however, it is likely that treatment will need to begin during the preclinical phase to prevent or limit plaque accumulation to be beneficial in reducing the risk of developing AD (51, 52).”
From Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans (2011) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“New clinical diagnostic consensus criteria have now been finalized under the auspices of the NIA and Alzheimer's Association (52), with novel features including recognition of a preclinical stage of AD and the incorporation of imaging and laboratory-based cerebrospinal fluid biomarkers.”
From Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 (2012) · cites this paper as [52]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Alzheimer’s disease (AD) begins several decades before the clinical onset of dementia with progressive amyloid accumulation preceding significant tau pathology and neurodegeneration.10,11”
From Machine learning reveals prominent spontaneous behavioral changes and treatment efficacy in humanized and transgenic Alzheimer's disease models (2024) · cites this paper as [11]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Because there is evidence that the pathophysiology of AD likely begins many years before the emergence of clinical symptoms or a syndrome such as MCI or dementia”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“Nevertheless, after decades of research, both the etiology and the pathophysiologic sequence of AD remain uncertain [102]”
From The Need to Separate Chronic Traumatic Encephalopathy Neuropathology from Clinical Features (2017) · cites this paper as [102]
The cited source says what the claim attributes to it.
In the citing paper
“This unifying research framework is a natural descendant of the 2011 NIA-AA preclinical AD recommendations that were based on the concept that AD, identified by biomarkers, can exist in the absence of symptoms [4].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [4]
The cited source says what the claim attributes to it.
In the citing paper
“Clinico-pathologic correlations for individuals without cognitive impairment should indicate that it is possible for AD neuropathologic change to predate onset of symptoms by years [54].”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“recognition that AD neuropathologic changes may occur in the apparent absence of cognitive impairment”
From National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach (2012) · cites this paper as [54]
The cited source says what the claim attributes to it.
In the citing paper
“This later point is important as the pathophysiological changes in the brain of people with AD require several years to occur.16”
From Cumulative Use of Strong Anticholinergics and Incident Dementia: A Prospective Cohort Study (2015) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The timing of therapeutic treatment in AD seems to be crucial as studies have shown that treating the disease too late has little efficacy (Sperling et al., 2011; Yiannopoulou et al., 2019).”
From Inhibiting USP16 rescues stem cell aging and memory in an Alzheimer’s model (2022) · cites this paper as Sperling et al., 2011
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“But their high cost and insufficient accessibility are being major limitations [12].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“individuals remain cognitively normal for many years despite accumulating aggregates of Aβ plaques and tau neurofibrillary tangles (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“The neuropathological changes of Alzheimer’s disease (AD) begin two decades or more before signs of cognitive impairment (Sperling et al., 2011).”
From A Multi-network Approach Identifies Protein-Specific Co-expression in Asymptomatic and Symptomatic Alzheimer’s Disease (2017) · cites this paper as Sperling et al., 2011
In the citing paper
“Additionally, we used the old criteria for the preclinical AD definition, while the recent research criteria also require tau positivity [8].”
From Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and APOE genotype (2019) · cites this paper as [8]
In the citing paper
“Plaque formation rates also vary over time [217]. After a period of rapid accumulation, plaque deposition gradually slows and by the time symptoms manifest plaque deposition is essentially done [20, 205, 218].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“The amyloid cascade hypothesis [14, 15], in conjunction with the newly designated preclinical AD category [20], necessarily infers cognitive changes that arise before plaques appear are etiologically unrelated to cognitive changes that arise after plaques appear.”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [20]
In the citing paper
“In addition to using Aβ phenomena to distinguish AD from “normal” brain aging, the new criteria make one critical mechanistic assumption. Aβ is identified as an “upstream” AD biomarker [77]. Other biomarkers, including increased CSF tau, CSF phospho-tau, and decreased glucose utilization (as demonstrated by fluorodeoxyglucose PET; FDG PET), are identified as “downstream” biomarkers.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new AD diagnostic criteria cognitive decline and an absence of alternative dementia-associated pathology are no longer required features. At least for research purposes, to qualify for a diagnosis of AD altered brain or CSF Aβ is now the sole requirement [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This is reflected by the recent adoption of AD diagnostic criteria that classify cognitively normal individuals with brain plaques or low cerebrospinal fluid Aβ levels as having “preclinical AD” [77].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“Studies of non-demented elderly cohorts overall report approximately 20–40% are PIB-positive [67, 68, 71–78].”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“According to the new criteria, the primary dividing line between AD and brain aging is the presence or absence of brain or CSF Aβ changes.”
From Brain aging, Alzheimer's disease, and mitochondria (2011) · cites this paper as [77]
In the citing paper
“This asymptomatic phase of AD (AsymAD) is currently considered a preclinical stage of the disease [27, 28].”
From Deep proteomic network analysis of Alzheimer’s disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease (2018) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Self-citationNeuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“ries [68]) and the clinical syndrome of AD dementia (estimated prevalence from three epidemiological studies [69–71]).”
BackgroundAlbert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 1×
“This long “preclinical” phase of AD would provide a critical opportunity for therapeutic intervention; however, we need to further elucidate the link between the pathological cascade of AD and the emergence of clinical symptoms.”
BackgroundSelf-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationAlzheimer's Disease Is a Synaptic Failure
Selkoe, D. J. (2002) · Science · doi:10.1126/science.1074069 · Cited by 4,420
Shankar, G. M., Li, S., Mehta, T. H., Garcia-Munoz, A., Shepardson, N. E., Smith, I., Brett, F. M., Farrell, M. A., Rowan, M. J., Lemere, C. A., et al. (2008) · Nature Medicine · doi:10.1038/nm1782 · Cited by 3,685
Stern, Y. (2009) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2009.03.004 · Cited by 2,943
Self-citationDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationJack, C. R., Albert, M. S., Knopman, D. S., McKhann, G. M., Sperling, R. A., Carrillo, M. C., Thies, B., & Phelps, C. H. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.004 · Cited by 2,042
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- JABecker DRentz JSCarmasin THedden IHamdi RLBuckner et al.Amyloid deposition and brain volume across the continuum of aging and AD.Ann Neurol2011(in press)
Cited by
Sorted by citations
Items 701–800 of 1,158
Wirth, M., Haase, C. M., Villeneuve, S., Vogel, J. W., & Jagust, W. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.015 · Cited by 138
Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer’s Disease Diagnosis
Bjerke, M., & Engelborghs, S. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170680 · Cited by 137
Subthreshold Amyloid Predicts Tau Deposition in Aging
Leal, S. L., Lockhart, S. N., Maaß, A., Bell, R. K., & Jagust, W. J. (2018) · Journal of Neuroscience · doi:10.1523/jneurosci.0485-18.2018 · Cited by 137
Gatchel, J. R., Rabin, J. S., Buckley, R. F., Locascio, J. J., Quiroz, Y. T., Yang, H., Vannini, P., Amariglio, R. E., Rentz, D. M., Properzi, M. J., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.8964 · Cited by 137
Self-citationMoreira, N. C. D. S., Lima, J. E. B. D. F., Marchiori, M. F., Carvalho, I., & Sakamoto‐Hojo, E. T. (2022) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-210061 · Cited by 137
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Self-citationMarkers of neuroinflammation associated with Alzheimer’s disease pathology in older adults
Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., Henry, H., Kirkland, R., Severin, I., Wojcik, J., et al. (2017) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2017.01.020 · Cited by 136
Hansson, O., Batrla, R., Brix, B., Carrillo, M. C., Corradini, V., Edelmayer, R. M., Esquivel, R. N., Hall, C., Lawson, J., Bastard, N. L., et al. (2021) · Alzheimer's & Dementia · doi:10.1002/alz.12316 · Cited by 136
Self-citationRahman, M. R., Islam, T., Zaman, T., Shahjaman, M., Karim, M. R., Huq, F., Quinn, J. M. W., Holsinger, R. M. D., Gov, E., & Moni, M. A. (2020) · Genomics · doi:10.1016/j.ygeno.2019.07.018 · Cited by 136
The role of egocentric and allocentric abilities in Alzheimer's disease: A systematic review
Serino, S., Cipresso, P., Morganti, F., & Riva, G. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.04.004 · Cited by 136
The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer’s Disease
Deardorff, W. J., Feen, E. S., & Grossberg, G. T. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0273-x · Cited by 136
Research Gaps and Controversies in Chronic Traumatic Encephalopathy: A Review
Asken, B. M., Sullan, M. J., DeKosky, S. T., Jaffee, M. S., & Bauer, R. M. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2396 · Cited by 135
APOE-by-sex interactions on brain structure and metabolism in healthy elderly controls
Sampedro, F., Initiative, F. T. A. D. N., Vilaplana, E., de Leon, M. J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M., Sala, I., Sánchez-Saudinos, M.-B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5185 · Cited by 135
Harrison, J. K., Fearon, P. A., Noel-Storr, A. H., McShane, R. H., Stott, D. J., & Quinn, T. J. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010772.pub2 · Cited by 135
The Role and Therapeutic Targeting of α-, β- and γ-Secretase in Alzheimer's Disease
MacLeod, R., Hillert, E., Cameron, R. T., & Baillie, G. S. (2015) · Future Science OA · doi:10.4155/fso.15.9 · Cited by 136
Amyloid tracers detect multiple binding sites in Alzheimer's disease brain tissue
Ni, R., Gillberg, P., Bergfors, A., Marutle, A., & Nordberg, A. K. (2013) · Brain · doi:10.1093/brain/awt142 · Cited by 135
Early Postmenopausal Transdermal 17β-Estradiol Therapy and Amyloid-β Deposition
Kantarci, K., Lowe, V. J., Lesnick, T. G., Tosakulwong, N., Bailey, K. R., Fields, J. A., Shuster, L. T., Zuk, S. M., Senjem, M. L., Mielke, M. M., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160258 · Cited by 135
Self-citationLeuzy, A., Chiotis, K., Hasselbalch, S. G., Rinne, J. O., de Mendonça, A., Otto, M., Lleó, A., Castelo-Branco, M. S., Santana, I. J., Johansson, J. J., et al. (2016) · Brain · doi:10.1093/brain/aww160 · Cited by 135
Early Detection of Alzheimer's Disease with Blood Plasma Proteins Using Support Vector Machines
Eke, C. S., Jammeh, E., Li, X., Carroll, C., Pearson, S., & Ifeachor, E. (2020) · IEEE Journal of Biomedical and Health Informatics · doi:10.1109/jbhi.2020.2984355 · Cited by 136
Chakrabarti, S., Kumar Khemka, V., Banerjee, A., Chatterjee, G., Ganguly, A., & Biswas, A. (2015) · Aging and disease · doi:10.14336/ad.2014.002 · Cited by 134
Cerebral perfusion in the predementia stages of Alzheimer’s disease
Binnewijzend, M. A. A., Benedictus, M. R., Kuijer, J. P. A., van der Flier, W. M., Teunissen, C. E., Prins, N. D., Wattjes, M. P., van Berckel, B. N. M., Scheltens, P., & Barkhof, F. (2015) · European Radiology · doi:10.1007/s00330-015-3834-9 · Cited by 134
Wallon, D., The collaborators of the GMAJ project, Rousseau, S., Rovelet‐Lecrux, A., Quillard‐Muraine, M., Guyant‐Maréchal, L., Martinaud, O., Pariente, J., Puel, M., Rollin‐Sillaire, A., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120172 · Cited by 134
Nunomura, A., Tamaoki, T., Motohashi, N., Nakamura, M., McKeel, D. W., Tabaton, M., Lee, H., Smith, M. A., Perry, G. L., & Zhu, X. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318248e614 · Cited by 134
Langbaum, J. B. S., Hendrix, S. B., Ayutyanont, N., Chen, K., Fleisher, A., Shah, R. C., Barnes, L. L., Bennett, D. A., Tariot, P. N., & Reiman, E. M. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.02.002 · Cited by 134
Self-citationBlood and plasma-based proteomic biomarker research in Alzheimer's disease
Lista, S., Faltraco, F., Prvulovic, D., & Hampel, H. J. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.007 · Cited by 134
Sabuncu, M. R., Buckner, R. L., Smoller, J. W., Lee, P. H., Fischl, B. R., & Sperling, R. A. (2011) · Cerebral Cortex · doi:10.1093/cercor/bhr348 · Cited by 134
Self-citationQuantitative proteomics reveals distinct composition of amyloid plaques in Alzheimer’s disease
Xiong, F., Ge, W., & Ma, C. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.10.006 · Cited by 133
Lin, C., Chen, P.-K., Chang, Y., Chuo, L.-J., Chen, Y.-S., Tsai, G. E., & Lane, H. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.08.010 · Cited by 133
Lineweaver, T. T., Bondi, M. W., Galasko, D. R., & Salmon, D. P. (2013) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.12121590 · Cited by 133
The role of exosomes in the pathogenesis of Alzheimer’ disease
Xiao, T., Zhang, W., Jiao, B., Pan, C., Liu, X., & Shen, L. H. (2017) · Translational Neurodegeneration · doi:10.1186/s40035-017-0072-x · Cited by 133
Bruderer‐Hofstetter, M., Osthoff, A.-K. R., Meichtry, A., Münzer, T., & Niedermann, K. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2018.04.002 · Cited by 133
Multi-method investigation of factors influencing amyloid onset and impairment in three cohorts
Betthauser, T. J., Bilgel, M., Koscik, R. L., Jedynak, B., An, Y., Kellett, K. A., Moghekar, A., Jonaitis, E. M., Stone, C. K., Engelman, C. D., et al. (2022) · Brain · doi:10.1093/brain/awac213 · Cited by 133
Binette, A. P., Gaiteri, C., Wennström, M., Kumar, A., Hristovska, I., Spotorno, N., Salvadó, G., Strandberg, O. T., Mathys, H., Tsai, L., et al. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01737-w · Cited by 146
Association between consumption of ultraprocessed foods and cognitive decline
Gomes Gonçalves, N., Vidal Ferreira, N., Khandpur, N., Martinez Steele, E., Bertazzi Levy, R., Andrade Lotufo, P., Bensenor, I. M., Caramelli, P., Alvim de Matos, S. M., Marchioni, D. M., et al. (2023) · JAMA Neurology · doi:10.1001/jamaneurol.2022.4397 · Cited by 132
Miebach, L., Wolfsgruber, S., Polcher, A. A., Peters, O., Menne, F., Luther, K., Incesoy, E. I., Priller, J., Spruth, E. J., Altenstein, S., et al. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0515-y · Cited by 132
Farrell, M. E., Jiang, S., Schultz, A. P., Properzi, M. J., Price, J. C., Becker, J. A., Jacobs, H. I. L., Hanseeuw, B. J., Rentz, D. M., Villemagne, V. L., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000011214 · Cited by 132
Self-citationPET imaging of synaptic density: A new tool for investigation of neuropsychiatric diseases
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., & Huang, Y. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.07.038 · Cited by 131
When Does Alzheimer′s Disease Really Start? The Role of Biomarkers
Lloret, A., Esteve, D., Lloret, M.-A., Cervera-Ferri, A., Lopez, B., Nepomuceno, M., & Monllor, P. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225536 · Cited by 131
Progression of mild cognitive impairment to dementia due to AD in clinical settings
Tifratène, K., Robert, P. H., Metelkina, A., Pradier, C., & Dartigues, J. (2015) · Neurology · doi:10.1212/wnl.0000000000001788 · Cited by 131
Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis
Harper, L., Bouwman, F. H., Burton, E. J., Barkhof, F., Scheltens, P., O'Brien, J. T., Fox, N. C., Ridgway, G. R., & Schott, J. M. (2017) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314978 · Cited by 131
Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results
Slot, R. E. R., Verfaillie, S. C. J., Overbeek, J. M., Timmers, T., Wesselman, L. M. P., Teunissen, C. E., Dols, A., Bouwman, F. H., Prins, N. D., Barkhof, F., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0390-y · Cited by 131
Modular machine learning for Alzheimer's disease classification from retinal vasculature
Tian, J., Smith, G. E., Guo, H. W., Liu, B., Pan, Z., Wang, Z., Xiong, S., & Fang, R. (2021) · Scientific Reports · doi:10.1038/s41598-020-80312-2 · Cited by 131
Vascular factors and multiple measures of early brain health: CARDIA brain MRI study
Launer, L. J., Lewis, C. E., Schreiner, P. J., Sidney, S., Battapady, H., Jacobs, D. R., Lim, K. O., D’Esposito, M., Zhang, Q., Reis, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0122138 · Cited by 130
n-3 LCPUFA improves cognition: The young, the old and the sick
Joffre, C., Nadjar, A., Lebbadi, M., Calon, F., & Layé, S. (2014) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2014.05.001 · Cited by 130
Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies
Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 130
Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults
Farrell, M. E., Chen, X., Rundle, M. M., Chan, M. Y., Wig, G. S., & Park, D. C. (2018) · Neurology · doi:10.1212/wnl.0000000000006469 · Cited by 130
Self-citationExploring the relationship between physical activity, beta-amyloid and tau: A narrative review
Brown, B. M., Peiffer, J. J., & Rainey‐Smith, S. R. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.01.003 · Cited by 130
Lleó, A., Alcolea, D. A., Martínez‐Lage, P., Scheltens, P., Parnetti, L., Poirier, J., Simonsen, A. H., Verbeek, M. M., Rosa‐Neto, P., Slot, R. E. R., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.01.015 · Cited by 130
Basher, A., Kim, B. C., Lee, K. H., & Jung, H. Y. (2021) · IEEE Access · doi:10.1109/access.2021.3059658 · Cited by 130
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Self-citationJack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129
Self-citationHampel, H., Toschi, N., Baldacci, F., Zetterberg, H., Blennow, K., Kilimann, I., Teipel, S. J., Cavedo, E., Melo dos Santos, A., Epelbaum, S., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.11.015 · Cited by 129
Binnewijzend, M. A. A., Adriaanse, S. M., van der Flier, W. M., Teunissen, C. E., de Munck, J. C., Stam, C. J., Scheltens, P., van Berckel, B. N. M., Barkhof, F., & Wink, A. M. (2013) · Human Brain Mapping · doi:10.1002/hbm.22335 · Cited by 129
Perspective: Prevention is better than cure
Gandy, S. (2011) · Nature · doi:10.1038/475s15a · Cited by 129
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V. J., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 129
Self-citationLeptin Dysfunction and Alzheimer’s Disease: Evidence from Cellular, Animal, and Human Studies
McGuire, M. J., & Ishii, M. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-015-0282-7 · Cited by 129
Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weıntraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B. S., Park, D. C., Ropacki, M. T., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.01.003 · Cited by 129
Self-citationExtracellular Vesicle as a Source of Alzheimer’s Biomarkers: Opportunities and Challenges
Lee, S., Mankhong, S., & Kang, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071728 · Cited by 129
van Wijk, N., Broersen, L. M., de Wilde, M. C., Hageman, R. J. J., Groenendijk, M., Sijben, J. W. C., & Kamphuis, P. J. G. H. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130998 · Cited by 128
Tariot, P. N., Lopera, F., Langbaum, J. B., Thomas, R. G., Hendrix, S., Schneider, L. S., Rios‐Romenets, S., Giraldo, M., Acosta, N., Tobon, C., et al. (2018) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.02.002 · Cited by 128
Self-citationFast, R., Schütt, T., Toft, N., Møller, A., & Berendt, M. (2013) · Journal of Veterinary Internal Medicine · doi:10.1111/jvim.12109 · Cited by 128
Can we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Self-citationWang, J., Bi, W., Cheng, A., Freire, D., Vempati, P., Zhao, W., Gong, B., Janle, E. M., Chen, T., Ferruzzi, M. G., et al. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00042 · Cited by 128
Tau imaging in neurodegenerative diseases
Dani, M., Brooks, D. J., & Edison, P. (2015) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-015-3231-2 · Cited by 128
Nicotinic Acetylcholine Receptor Agonists for the Treatment of Alzheimer’s Dementia: An Update
Hoskin, J. L., Al-Hasan, Y. M., & Sabbagh, M. N. (2018) · Nicotine & Tobacco Research · doi:10.1093/ntr/nty116 · Cited by 128
Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology
Wang, H.-F., Zhang, W., Rolls, E. T., Li, Y., Wang, L., Ma, Y., Kang, J., Feng, J., Yu, J., & Cheng, W. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104336 · Cited by 128
Brain metabolic maps in Mild Cognitive Impairment predict heterogeneity of progression to dementia
Cerami, C., Della Rosa, P. A., Magnani, G., Santangelo, R., Marcone, A., Cappa, S. F., & Perani, D. (2015) · NeuroImage: Clinical · doi:10.1016/j.nicl.2014.12.004 · Cited by 127
Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., Reiman, E. M., Fleisher, A., Sabbagh, M. N., Sadowsky, C., Carpenter, A. P., Davis, M. D., Lu, M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.014 · Cited by 127
Self-citationOsorio, R. S., Ayappa, I. A., Mantua, J., Gumb, T., Varga, A. W., Mooney, A. M., Burschtin, O. E., Taxin, Z. H., During, E., Spector, N. C., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.12.030 · Cited by 127
Wolk, D. A., Zhang, Z., Boudhar, S., Clark, C. M., Pontecorvo, M. J., & Arnold, S. E. (2012) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2012-302548 · Cited by 127
Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease
Santos, C. Y., Johnson, L. N., Sinoff, S. E., Festa, E. K., Heindel, W. C., & Snyder, P. J. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.003 · Cited by 127
Agliardi, C., Guerini, F. R., Zanzottera, M., Bianchi, A., Nemni, R., & Clerici, M. (2019) · Molecular Neurobiology · doi:10.1007/s12035-019-1501-x · Cited by 127
Styliadis, C., Kartsidis, P. E., Paraskevopoulos, E., Ioannides, A. A., & Bamidis, P. D. (2015) · Neural Plasticity · doi:10.1155/2015/172192 · Cited by 126
Trajectory of white matter hyperintensity burden preceding mild cognitive impairment
Silbert, L. C., Dodge, H. H., Perkins, L. N., Sherbakov, L. O., Lahna, D. L., Erten‐Lyons, D., Woltjer, R. L., Shinto, L. H., & Kaye, J. A. (2012) · Neurology · doi:10.1212/wnl.0b013e3182661f2b · Cited by 127
Self-citationGlobal quantitative analysis of the human brain proteome and phosphoproteome in Alzheimer’s disease
Ping, L., Kundinger, S. R., Duong, D. M., Yin, L., Gearing, M., Lah, J. J., Levey, A. I., & Seyfried, N. T. (2020) · Scientific Data · doi:10.1038/s41597-020-00650-8 · Cited by 127
Obesity, leptin, and Alzheimer's disease
Lee, E. B. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06274.x · Cited by 126
Utilizing the Centiloid scale in cross-sectional and longitudinal PiB PET studies
Su, Y., Flores, S., Hornbeck, R. C., Speidel, B., Vlassenko, A. G., Gordon, B. A., Koeppe, R. A., Klunk, W. E., Xiong, C., Morris, J. C., et al. (2018) · NeuroImage: Clinical · doi:10.1016/j.nicl.2018.04.022 · Cited by 126
Epigenomics of Alzheimer's disease
Bennett, D. A., Yu, L., Yang, J., Srivastava, G. P., Aubin, C., & Jager, P. L. D. (2014) · Translational research · doi:10.1016/j.trsl.2014.05.006 · Cited by 126
Self-citationCalderón‐Garcidueñas, A. L., & Duyckaerts, C. J. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-802395-2.00023-7 · Cited by 126
Insulin resistance in Alzheimer's disease
Dineley, K. T., Jahrling, J. B., & Denner, L. A. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.09.001 · Cited by 125
Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.005 · Cited by 125
BDNF Val66Met, Aβ amyloid, and cognitive decline in preclinical Alzheimer's disease
Lim, Y. Y., Villemagne, V. L., Laws, S. M., Ames, D., Pietrzak, R. H., Ellis, K. A., Harrington, K. D., Bourgeat, P., Salvado, O., Darby, D., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.006 · Cited by 124
Self-citationPatterns of cognitive decline prior to dementia in persons with mild cognitive impairment
Cloutier, S., Chertkow, H., Kergoat, M.-J., Gauthier, S., & Belleville, S. (2015) · Journal of Alzheimer's Disease · doi:10.3233/jad-142910 · Cited by 124
Clinical and imaging features of mixed Alzheimer and vascular pathologies
Chui, H. C., & Ramirez-Gomez, L. (2015) · Alzheimer's Research & Therapy · doi:10.1186/s13195-015-0104-7 · Cited by 124
Mild Cognitive Impairment in Older Adults
Geda, Y. E. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0291-x · Cited by 124
Ihle‐Hansen, H., Thommessen, B., Wyller, T. B., Engedal, K., Øksengård, A. R., Stenset, V. T. V., Løken, K., Aaberg, M., & Fure, B. (2011) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000335361 · Cited by 125
Zhou, B., Liu, Y., Zhang, Z., An, N., Yao, H., Wang, P., Wang, L., Zhang, X., & Jiang, T. (2013) · Current Alzheimer Research · doi:10.2174/15672050113109990146 · Cited by 124
Ritchie, C. W., & Ritchie, K. A. (2012) · BMJ Open · doi:10.1136/bmjopen-2012-001893 · Cited by 124
Quiroz, Y. T., Schultz, A. P., Chen, K., Protas, H. D., Brickhouse, M. J., Fleisher, A., Langbaum, J. B. S., Thiyyagura, P., Fagan, A. M., Shah, A. R., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.1099 · Cited by 124
Self-citationMoya‐Alvarado, G., Gershoni‐Emek, N., Perlson, E., & Bronfman, F. C. (2016) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r115.053330 · Cited by 124
Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer’s disease
Benedictus, M. R., Leeuwis, A. E., Binnewijzend, M. A. A., Kuijer, J. P. A., Scheltens, P., Barkhof, F., van der Flier, W. M., & Prins, N. D. (2016) · European Radiology · doi:10.1007/s00330-016-4450-z · Cited by 124
Alzheimer's disease: The next frontier—Special Report 2017
Karlawish, J. H., Jack, C. R., Rocca, W. A., Snyder, H. M., & Carrillo, M. C. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.02.006 · Cited by 124
Self-citationMormino, E. C., & Papp, K. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179928 · Cited by 124
Jett, S., Malviya, N., Schelbaum, E., Jang, G., Jahan, E., Clancy, K., Hristov, H., Pahlajani, S. S., Niotis, K., Loeb‐Zeitlin, S., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.831807 · Cited by 124
Sperling, R. A., Donohue, M., Rissman, R. A., Johnson, K. A., Rentz, D. M., Grill, J. D., Heidebrink, J. L., Jenkins, C., Jimenez‐Maggiora, G. A., Langford, O., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.122 · Cited by 124
Self-citationMagnetic Resonance Spectroscopy in Alzheimer’s Disease: Systematic Review and Meta-Analysis
Wang, H., Tan, L., Wang, H.-F., Liu, Y., Yin, R.-H., Wang, W.-Y., Chang, X.-L., Jiang, T., & Yu, J.-T. (2015) · Journal of Alzheimer’s Disease · doi:10.3233/jad-143225 · Cited by 123
Prevalence of preclinical Alzheimer disease
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Wærn, M., Höglund, K., Andréasson, U., Wetterberg, H., Börjesson‐Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 123
Baldeiras, I., Santana, I. J., Leitão, M. J., Gens, H., Pascoal, R., Tábuas‐Pereira, M., Beato-Coelho, J., Duro, D., Almeida, M. R., & Oliveira, C. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0362-2 · Cited by 123
Association between chronic stress and Alzheimer’s disease: Therapeutic effects of Saffron
Saeedi, M., & Rashidy‐Pour, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110995 · Cited by 123
Apathy correlates with prefrontal amyloid deposition in Alzheimer's disease
Mori, T., Shimada, H., Shinotoh, H., Hirano, S., Eguchi, Y., Yamada, M., Fukuhara, R., Tanimukai, S., Zhang, M.-R., Kuwabara, S., et al. (2014) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2013-306110 · Cited by 122
Metadata
- Authors
- Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison‐Bogorad, M., Wagster, M. V., & Phelps, C. H.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California San Diego (US)
- University of California, Davis (US)
- Rush University Medical Center (US)
- University of Washington (US)
- Washington University in St. Louis (US)
- The University of Tokyo (JP)
- Mayo Clinic (US)
- Oregon Health & Science University (US)
- The University of Texas at Dallas (US)
- Banner Alzheimer’s Institute (US)
- The University of Melbourne (AU)
- Eli Lilly (United States) (US)
- Columbia University Irving Medical Center (US)
- San Francisco VA Medical Center (US)
- Alzheimer's Association Chicago IL USA
- Alzheimer's Association (US)
- National Institutes of Health (US)
- Corresponding author
- Sperling, Reisa A.
- ORCID
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2011-04-22
- Volume
- 7
- Issue
- 3
- Pages
- 280-292
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- PMC
- PMC3220946
- OpenAlex
- W2129497119
- Semantic Scholar
- 4718e61de2c928d77780b2a72fac704f18d8297b
- Cited by
- 7,155
- References
- 71
- Citations by year
- 2026: 375 · 2025: 467 · 2024: 485 · 2023: 445 · 2022: 534 · 2021: 575 · 2020: 550 · 2019: 533 · 2018: 513 · 2017: 471 · 2016: 468 · 2015: 461 · 2014: 417 · 2013: 418 · 2012: 302
- FWCI
- 277.90
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Alzheimer s & Dementia (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Columbia Academic Commons (Columbia University)
- Funders
- National Institute on Aging
- Pfizer
- Baxter International
- Johnson and Johnson
- Eli Lilly and Company
- Bayer
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- Alzheimer's disease, preclinical Alzheimer's disease
- MeSH terms
- Alzheimer Disease, Cognition Disorders, Humans, United States, Biomarkers, Practice Guidelines as Topic, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
